$1.16
+0.07 (+6.42%)
Open$1.14
Previous Close$1.09
Day High$1.19
Day Low$1.13
52W High$13.82
52W Low$9.24
Volume—
Avg Volume507.4K
Market Cap25.97M
P/E Ratio57.60
EPS$0.18
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+950.9% upside
Current
$1.16
$1.16
Target
$12.19
$12.19
$8.12
$12.19 avg
$14.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.46M | 3.60M | 3.02M |
| Net Income | 357.4K | 374.4K | 370.1K |
| Profit Margin | 10.3% | 10.4% | 12.2% |
| EBITDA | 792.9K | 795.7K | 655.2K |
| Free Cash Flow | 311.9K | 219.4K | 229.2K |
| Rev Growth | +0.8% | +2.8% | +23.9% |
| Debt/Equity | 0.35 | 0.28 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |